Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Claim 1 is pending and currently under prosecution.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claim(s) 1 is rejected under 35 U.S.C. 102(a)(2) as being anticipated by Kaplan et al (US 2019/0085080 A1; claiming priority date: 08/25/2017).
The applied reference has a common Applicant with the instant application. Based upon the earlier effectively filed date of the reference, it constitutes prior art under 35 U.S.C. 102(a)(2). This rejection under 35 U.S.C. 102(a)(2) might be overcome by: (1) a showing under 37 CFR 1.130(a) that the subject matter disclosed in the reference was obtained directly or indirectly from the inventor or a joint inventor of this application and is thus not prior art in accordance with 35 U.S.C. 102(b)(2)(A); (2) a showing under 37 CFR 1.130(b) of a prior public disclosure under 35 U.S.C. 102(b)(2)(B) if the same invention is not being claimed; or (3) a statement pursuant to 35 U.S.C. 102(b)(2)(C) establishing that, not later than the effective filing date of the claimed invention, the subject matter disclosed in the reference and the claimed invention were either owned by the same person or subject to an obligation of assignment to the same person or subject to a joint research agreement.
Kaplan teaches a method of treating a solid tumor in a human subject, comprising administering to the subject 10-20 mg/kg of an antibody that specifically binds to B7-H4. Kaplan teaches that the antibody that binds to B7-H4 comprises a heavy chain variable region (VH) CDR1-3 which match 100% to the instantly claimed SEQ ID Nos: 5-6-7, respectively, and a light chain variable region (VL) CDR-1-3 which match 100% to the instantly claimed SEQ ID Nos: 8-9-10, respectively. [see sequence alignments below] [0359-0365, 0375; Tables 3 and 4]
SEQUENCE ALIGNMENTS
SEQ ID NOS: 5-6-7
RESULT 1
US-16-111-064-464
(NOTE: this sequence has 8 duplicates in the database searched)
Sequence 464, US/16111064
Patent No. 11306144
GENERAL INFORMATION
APPLICANT: FIVE PRIME THERAPEUTICS, INC.
TITLE OF INVENTION: B7-H4 Antibodies and Methods of Use Thereof
FILE REFERENCE: 3986.0090004
CURRENT APPLICATION NUMBER: US/16/111,064
CURRENT FILING DATE: 2018-08-23
PRIOR APPLICATION NUMBER: 62/550,173
PRIOR FILING DATE: 2017-08-25
PRIOR APPLICATION NUMBER: 62/579,774
PRIOR FILING DATE: 2017-10-31
PRIOR APPLICATION NUMBER: 62/607,810
PRIOR FILING DATE: 2017-12-19
PRIOR APPLICATION NUMBER: 62/656,789
PRIOR FILING DATE: 2018-04-12
NUMBER OF SEQ ID NOS: 469
SEQ ID NO 464
LENGTH: 120
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antibody 20502 Variable Heavy Chain
Query Match 88.9%; Score 194.6; Length 120;
Best Local Similarity 47.0%;
Matches 39; Conservative 0; Mismatches 0; Indels 44; Gaps 2;
Qy 1 GSIKSGSYYW--------------GNIYYSGSTYYNPSLRS------------------- 27
|||||||||| |||||||||||||||||
Db 27 GSIKSGSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPSLRSRVTISVDTSKNQFSLKLSS 86
Qy 28 -----------AREGSYPNQFDP 39
||||||||||||
Db 87 VTAADTAVYYCAREGSYPNQFDP 109
SEQ ID NOS: 8-9-10
RESULT 1
US-16-111-064-12
(NOTE: this sequence has 17 duplicates in the database searched)
Sequence 12, US/16111064
Patent No. 11306144
GENERAL INFORMATION
APPLICANT: FIVE PRIME THERAPEUTICS, INC.
TITLE OF INVENTION: B7-H4 Antibodies and Methods of Use Thereof
FILE REFERENCE: 3986.0090004
CURRENT APPLICATION NUMBER: US/16/111,064
CURRENT FILING DATE: 2018-08-23
PRIOR APPLICATION NUMBER: 62/550,173
PRIOR FILING DATE: 2017-08-25
PRIOR APPLICATION NUMBER: 62/579,774
PRIOR FILING DATE: 2017-10-31
PRIOR APPLICATION NUMBER: 62/607,810
PRIOR FILING DATE: 2017-12-19
PRIOR APPLICATION NUMBER: 62/656,789
PRIOR FILING DATE: 2018-04-12
NUMBER OF SEQ ID NOS: 469
SEQ ID NO 12
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antibody 15461 Variable Light Chain
Query Match 81.6%; Score 109.3; Length 107;
Best Local Similarity 36.5%;
Matches 27; Conservative 0; Mismatches 0; Indels 47; Gaps 2;
Qy 1 RASQSVSSNLA---------------GASTRAT--------------------------- 18
||||||||||| |||||||
Db 24 RASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDF 83
Qy 19 -----QQYHSFPFT 27
|||||||||
Db 84 AVYYCQQYHSFPFT 97
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claim 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-2 and 8 of U.S. Patent No. 11,306,144 in view of Liu et al (US9676854 B2; Published 2014).
The U.S. Patent claims a method of treating a solid tumor comprising administering an antibody that specifically binds to B7-H4, comprising the instantly claimed sequences.
However, The U.S. Patent does not claim the wherein the B7-H4 antibody is administered at a dose of about 0.005 to about 20 mg/kg.
Liu teaches the method of treating cancer comprising administering an antibody that binds to B7-H4, wherein the B7-H4 antibody is administered to the subject at doses ranging from 0.005 mg/kg and 20 mg/kg. [Col. 46 lines 39-62]
It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was filed to treat solid tumors with administration of a B7-H4 antibody at a dose of about 0.005 to about 20 mg/kg. One would have been motivated to because the U.S. Patent and Liu teach and claim treating subjects having B7-H4 expressing tumors by administering the B7-H4 antibody. One of ordinary skill in the art would have reasonable expectation of success because Liu teaches and suggests administering B7-H4 antibody for cancer treatment at a dose of about 0.005 to about 20 mg/kg, for the same purpose to treat cancer as claimed by the U.S. Patent.
Claims 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 5, and 12 of U.S. Patent No. 11,814,431 in view of Liu et al (US9676854B2; Published 2014).
The U.S. Patent claims a method of treating a solid tumor comprising administering an antibody that specifically binds to B7-H4, comprising the instantly claimed sequences.
However, the U.S. Patent does not claim the wherein the B7-H4 antibody is administered at a dose of about 0.005 to about 20 mg/kg.
Liu teaches the method of treating cancer comprising administering an antibody that binds to B7-H4, wherein the B7-H4 antibody is administered to the subject at doses ranging from 0.005 mg/kg and 20 mg/kg. [Col. 46 lines 39-62]
It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was filed to treat solid tumors with administration of a B7-H4 antibody at a dose of about 0.005 to about 20 mg/kg. One would have been motivated to because the U.S. Patent and Liu teach and claim treating subjects having B7-H4 expressing tumors with the B7-H4 antibody. One of ordinary skill in the art would have reasonable expectation of success because Liu teaches and suggests administering B7-H4 antibody for cancer treatment at a dose of about 0.005 to about 20 mg/kg for the same purpose to treat cancer, as claimed by the U.S. Patent.
Conclusion
Conclusion: Claim 1 is rejected.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH A ALSOMAIRY whose telephone number is (571)272-0027. The examiner can normally be reached Monday-Friday 7:30 AM to 5:30 PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gregory Emch can be reached at (571) 272-8149. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SARAH A ALSOMAIRY/ Examiner, Art Unit 1646